country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

11 Results for "

MIN-6

" in MedChemExpress (MCE) Product Catalog:

Products (11)

Sort by :

Categories

By Targets

Products

LY 303511 hydrochloride

5 Cited Publications

Cat. No.: HY-15643A

CAS No.: 2070014-90-1

Purity: 98.87%

Target:

TNF Receptor Potassium Channel

Research Areas:

Cancer

LY 303511 hydrochloride is a structural analogue of LY294002. LY303511 does not inhibit PI3K. LY303511 enhances TRAIL sensitivity of SHEP-1 neuroblastoma cells. LY303511 reversibly blocks K ⁺ currents (IC₅₀=64.6±9.1 μM) in MIN6 insulinoma cells.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

DC260126

3 Cited Publications

Cat. No.: HY-101906

CAS No.: 346692-04-4

Purity: 99.57%

Target:

Free Fatty Acid Receptor Apoptosis

Research Areas:

Metabolic Disease

DC260126 is a potent antagonist of GPR40 (FFAR1). DC260126 dose-dependently inhibits GPR40-mediated Ca ²⁺ elevations stimulated by linoleic acid, oleic acid, palmitoleic acid and lauric acid (IC₅₀: 6.28, 5.96, 7.07, 4.58 μM, respectively) . DC260126 could protect MIN6 β cells from palmitate-induced ER stress and apoptosis .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Irsogladine

3 Cited Publications

Cat. No.: HY-B0327

CAS No.: 57381-26-7

Synonyms: DicloguaMINe

Target:

Phosphodiesterase (PDE) NF-κB AP-1 TRP Channel Interleukin Related

Research Areas:

Inflammation/Immunology Cancer

Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and K_ATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer ^[5][6] .

Compare